Infections with Candida krusei have increased in recent years as a consequence of its intrinsic resistance to uconazole, an antifungal azole widely used in immunocompromised individuals to suppress infections due to azole-susceptible C. albicans. One established mechanism for azole resistance is drug ef ux by ATP binding cassette (ABC) transporters. Since these transporters recognize structurally diverse drugs, their overexpression can lead to multidrug resistance (MDR). To identify C. krusei genes potentially involved in azole resistance, PCR was performed with primers corresponding to conserved sequences of MDR-related ABC transporters from other fungi. Two genes, ABC1 and ABC2, were identi ed; Southern blots suggested that both have one or two related gene copies in the C. krusei genome. ABC1 RNA was constitutively expressed at low levels in log phase cells while ABC2 RNA was undetectable. However, both genes were upregulated as cultures approached stationary phase, and this upregulation was correlated with decreased susceptibility to the lethal activity of the azole derivative miconazole. Furthermore, ABC1 was upregulated following brief treatment of C. krusei with miconazole and clotrimazole (but not other azoles), and the unrelated compounds albendazole and cycloheximide. The latter two compounds antagonized uconazole activity versus C. krusei, supporting a role for the ABC1 transporter in azole ef ux. Finally, miconazoleresistant mutants selected in vitro demonstrated increased constitutive expression of ABC1. Based on these expression data, genetic and functional characterization of the ABC1 transporter to directly test its role in C. krusei azole resistance would appear to be warranted.
Introduction
Opportunistic fungal infections have increased in recent decades due to increasing numbers of individuals who are immunosuppressed in association with organ and bone marrow transplantation, acquired immune deciency syndrome (AIDS) and certain therapies for cancer, allergy and autoimmune disease. The most common fungal opportunist is Candida albicans. Infections with this yeast are generally treated with uconazole or related antifungal azoles (e.g., ketoconazole, itraconazole and miconazole), which inhibit lanosterol demethylase in the ergosterol synthesis pathway. Clinical resistance to uconazole of some C. albicans strains has been correlated with increased expression of speci c multidrug resistance (MDR) ef ux proteins encoded by the CDR1, CDR2 and MDR1 genes (for reviews, see [1, 2] ). CDR1 and CDR2 encode ATP binding cassette (ABC) transporters that derive their energy from ATP hydrolysis, while MDR1 (formerly called BEN r ) encodes a member of the major facilitator superfamily that derives its energy from the proton gradient across the cytoplasmic membrane. In other C. albicans strains, uconazole resistance has been associated with alterations in, or upregulation of, lanosterol demethylase itself [3] .
C. krusei is intrinsically resistant to uconazole (minimum inhibitory concentration [MIC] typically
¶ 32 m g ml
¡1
) and has relatively low susceptibility to ketoconazole [4, 5] . Not surprisingly, the increased use in recent years of uconazole for therapy and prophylaxis has been associated with an increased incidence of C. krusei infection [6] . Itraconazole represents an alternative agent; however, itraconazole-resistant strains have been reported [7] . The basis for azole resistance in C. krusei has been examined in several studies, with somewhat contradictory results. Marichal et al. [4] and Venkateswarlu et al. [8] reported relatively small differences in binding and inhibitory activity of uconazole, itraconazole and ketoconazole to C. krusei lanosterol demethylase. Conversely, relatively large differences in intracellular accumulation of these azoles were noted, which correlate with their different effects on growth [4] . Reduced accumulation was similarly identi ed by Venkateswarlu et al. [7] as the basis for itraconazole resistance in a clinical isolate. In contrast, Orozco et al. [9] observed a large difference in the cellfree inhibition by uconazole of C. krusei and C. albicans lanosterol demethylase and no signi cant difference in uconazole accumulation. The lanosterol demethylase gene, ERG11, has been cloned from a variety of fungal species including C. krusei and this will facilitate further studies of lanosterol demethylase-based resistance. On the other hand, there are no reports describing C. krusei MDR transporters or the genes encoding them. Genome sequencing has revealed that ABC transporters are encoded by large gene families. In Saccharomyces cerevisiae, 23 such genes have been identi ed; of these, PDR5 and SNQ2 have been most strongly implicated in MDR [10, 11] . Similarly, C. albicans encodes multiple ABC transporters of which only CDR1 and CDR2 are known to transport drugs, including azoles [12] . MDR-related ABC transporter genes have also been identi ed in Aspergillus nidulans [13] and C. glabrata [14, 15] .
We have used primers based on conserved sequences within fungal MDR-associated ABC transporters to amplify fragments of two C. krusei genes, ABC1 and ABC2. RNA expression studies and correlations with azole susceptibility indicate a potential role for at least one of these genes in C. krusei intrinsic or acquired azole resistance. (Portions of the work reported here have been previously presented [16] .) C. All drugs were obtained from Sigma (St. Louis, MO, USA) with the exception of uconazole (P zer, New York, NY, USA) and ketoconazole (Janssen, Titusville, NJ, USA), and were dissolved in 0¢9% saline ( uconazole) or DMSO (all others). Drug stocks were diluted to a nal DMSO concentration µ 0¢5%.
Materials and methods

Strains
Ampli cation, cloning and sequencing
Degenerate primers were designed based on conserved amino acid sequences within the carboxy terminal ABC domains of known fungal MDR transporters (see Fig. 1 ). The forward primer was 5 0 -CGGTGCCGGMAAGAC-GAC and the reverse primer was 5 0 -GATGTG-GGTTCGTCMAGGAA (MˆA/C). Ampli cation of C. krusei DNA (see below) with Taq polymerase was performed as recommended by the manufacturer (Promega, Madison, WI, USA). Samples were cycled three times with annealing at Products were separated by agarose gel electrophoresis, stained with ethidium bromide, and the major band at approximately 0¢4 kbp was cut out. The DNA was puri ed using Prep-a-Gene (BioRad, Hercules, CA, USA) and ligated to the Ttailed vector pGEM-T (Promega). Following transformation, plasmid screening identi ed two distinct inserts, and DNA from representative clones was sequenced on both strands using Sequenase as recommended (USB, Cleveland, OH, USA). A C. krusei actin gene fragment was ampli ed as described above using primers (ACT2F and ACT3R) corresponding to conserved actin amino acids 79 to 85 (5 0 -TGGGATGATATGGAGAAGAT) and 351 to 357 (ATCCACATTTGTTGGAAKGT; K = G/T).
Phylogenetic analysis employed the programs PILEUP, DISTANCES (Kimura correction), and GROWTREE (Neighbor-Joining method) from the GCG package (Madison, WI, USA).
Southern blot analysis
Overnight C. krusei cultures (2 ml) were centrifuged, the cells suspended in 0¢2 ml 20 mM Tris (pH 7¢6), 2 mM EDTA, 5 mM dithiothreitol with 0¢2 mg yeast lytic enzyme (ICN, Cleveland, OH, USA), and incubated at 37 o C for 30 min. An equal volume of 50 mM Tris, 5 mM EDTA, 150 mM NaCl, 0¢4% sodium dodecyl sulfate (SDS) (pH 7¢5) with 0¢2 mg proteinase K (Sigma) was added and the mixture incubated at 55 o C for 20 min followed by 37 o C for 1 h. DNA was extracted with phenol followed by chloroform and precipitated twice in ethanol. Following suspension in water, DNA (1¢5 m g) was digested with BamHI, BglII, EcoRI, HincII, HindIII or PstI restriction enzymes (5 units) as recommended by the manufacturer (Promega). The digests were electrophoresed, blotted onto nitrocellulose, and hybridized by standard procedures [17] to gel-puri ed cloned ABC1 or ABC2 DNA fragments labelled with 32 P by random priming (Promega). Blots were washed in 0¢1 £ SSPE (1 £ SSPE: 0¢18 M NaCl, 10 mM sodium phosphate, 10 mM EDTA, pH 7¢4) plus 0¢1% SDS at 55 o C and autoradiographed. and PDR5 gene products. Only residues which differ from the consensus sequence (CONS; corresponding to residues present in more than three of the six sequences, with hyphens representing lack of consensus) are shown. Dots represent gaps introduced to maximize alignment. Conserved sequences within the carboxy-terminal ABC domains that were used to design the PCR primers are underlined. (b) Phylogenetic tree of carboxy-terminal ABC domains of ABC transporters from C. krusei (Ck), C. albicans (Ca), C. glabrata (Cg) and S. cerevisiae (Sc; group I only). Following an additional incubation for 20 min with gentle shaking, cultures were cooled on ice. RNA was puri ed by modi cations of previously described methods [18, 19] . Cultures were centrifuged brie y and the cell pellets suspended in 0¢2 ml cold 50 mM sodium acetate, 10 mM EDTA (pH 5¢0) buffer. A 0¢1 ml volume of acidwashed glass beads (0¢3 mm diameter), 20 m l of 10% SDS, and 0¢2 ml sodium acetate/EDTA buffer-saturated phenol (preheated to 65 o C) were added and RNA extracted by vigorous vortexing alternating with incubation at 65 o C for a total of 15 min. Samples were transferred to ice for 5 min and then centrifuged at 16 000 g for 5 min. The aqueous phase was transferred to a new tube and RNA precipitated overnight at ¡20 o C in 0¢3 M sodium acetate and threee volumes of ethanol. After centrifugation, RNA pellets were dissolved in 0¢5 ml water and denatured by addition of 0¢3 ml 20£ SSPE and 0¢2 ml formaldehyde (37%) with incubation at 60 o C for 15 min. Samples were applied to nylon membranes using a slot-blot apparatus as recommended by the manufacturer (BioRad). Membranes were rinsed in 2£ SSPE and UV crosslinked, then hybridized to random primed 32 P-labelled DNA probes by standard procedures [17] . Blots were washed at high stringency (0¢1£ SSPE/0¢1% SDS at 65 o C) and autoradiographed.
Drug treatment, RNA isolation and slot-blot analysis
Isolation and analysis of drug-resistant mutants
Log-phase C. krusei cells (1 £ 10 7 ) were plated on YPD agar containing 2 m g ml ¡1 miconazole or cycloheximide (20-40 £ MIC). After 48 h incubation, approximately 1000 miconazole and 60 cycloheximide-resistant colonies were observed, several of which were restreaked on drug-containing plates to con rm resistance and obtain isolated colonies. Fresh colonies from these plates were cultured overnight in YPD without drug (cells remained fully resistant after this drug-free passage). Cultures were diluted 30-fold into 2 ml of fresh YPD, incubated for 3 h at 30 o C to a density of 2 £ 10 7 cells ml
¡1
, and the RNA analyzed as above.
Assays of fungicidal activity and in vitro antagonism
To examine the effects of growth phase on C. krusei susceptibility to miconazole-dependent killing [20] , a fresh overnight culture was diluted 1:10, 1:100 and 1:1000 in YPD and incubated for 4 h with rotation. The cultures were then diluted to approximately equal cell density (2-3 £ 10 5 cells ml ¡1 ), split into two equal portions, and treated for 20 min with miconazole (10 m g ml ¡1 ) or DMSO vehicle. Aliquots (110 m l) were plated on drugfree YPD agar, the plates incubated for 24 h, and colonies counted.
To examine antagonism, log phase cultures were diluted to 1 £ 10 3 cells ml ¡1 and 0¢5 ml aliquoted to wells of a 24-well at-bottomed culture plate. Fluconazole was added by serial two-fold dilution, and albendazole or cycloheximide added to the required concentrations; controls received drug vehicle. Plates were incubated with shaking at 30 o C and cell numbers were determined using a hemocytometer after 18 h of incubation. The results are expressed as the ratio of cell numbers in cultures treated with the drug combination versus uconazole alone.
Results
Identi cation of C. krusei ABC transporter genes
The amino acid sequences of known fungal MDRassociated ABC transporters (see Introduction) were aligned to identify conserved residues. ABC transporters are large proteins (¹1500 amino acids) that typically possess two ABC domains and two transmembrane (TM) domains, and in fungal MDR-associated transporters these domains are arranged ABC-TM-ABC-TM. From the alignment, primers were designed that partially overlap the coding sequences for the Walker A and B boxes [21] within the carboxy-terminal ABC domain. Ampli cation of C. krusei DNA with this primer pair generated a major band with the expected size of approximately 0¢4 kbp. Cloning and sequencing of this DNA identi ed two ABC transporter gene homologs, ABC1
and ABC2 (deposited in GenBank [www.ncbi.nlm.nih.gov] with accession numbers AF250036 and AF250037). Their predicted amino acid sequences are aligned in Fig. 1a with the corresponding regions from known fungal MDR transporters.
As expected, BLAST and FASTA analyses indicate that both C. krusei sequences are most closely related to S. cerevisiae cluster I.1 ABC transporters [11] . Speci cally, ABC1 is most closely related to the PDR5 group (73-75% identity) while ABC2 is most closely related to the SNQ2 group (70-71% identity). These relationships were con rmed by phylogenetic analysis (Fig. 1b) . The two C. glabrata MDR-associated transporters [14, 15] also cluster with PDR5, while the C. albicans CDR1-CDR4 transporters are more distantly related. Note, however, that these analyses are based on small segments (¹120 residues) of these proteins.
Southern blot analysis
Since ABC transporters are encoded typically by large gene families, Southern blot analysis was performed to determine if ABC1 or ABC2 have close homologs in the C. krusei genome. One restriction enzyme (HincII) which cleaves asymmetrically within the cloned ABC1 and ABC2 probes was employed (which should therefore generate at least one strong and one weaker band) in addition to several enzymes which lack cleavage sites within the probes. As shown in Figure 2 , a single strong band and two or three weaker bands were detected in HincII-cleaved DNA probed with both ABC1 and ABC2. Similarly, the other enzymes generated a single strong band and up to two weaker bands. Where weak bands are absent, it is possible that the single strong band represents multiple gene copies forming bands of the same size. The results suggest that both ABC1 and ABC2 have one or two close homologs. This would be analogous to the situation in S. cerevisiae and C. albicans (Fig. 1b) .
Growth phase-dependent expression of ABC1 and ABC2
In mid-log phase cells ( < 4 £ 10 7 cells ml ¡1 ), ABC1 is expressed at low levels while ABC2 RNA is undetectable (2 and 4 h; Fig. 3 ). However, both genes are strongly upregulated in late log (1 £ 10 8 cells ml
¡1
), and RNA levels remain high through early stationary phase (8-23 h; Fig. 3 ).
Growth phase-dependent azole susceptibility
To examine the potential relevance of growth phasedependent expression of ABC transporters on azole susceptibility, a rapid killing assay [20] was employed. A C. krusei stationary phase culture was diluted to varying extents into fresh medium and incubated for 4 h. Cell densities were adjusted to approximately equal levels, cultures were treated with a fungicidal concentration of miconazole (10 m g ml ¡1 ) for 20 min, then plated on drug-free medium. In cultures diluted 1:100 and 1:1000, miconazole treatment resulted in a 7-8-fold decrease in cfu (3¢8 and 5¢4 £ 10 4 cfu ml ¡1 in treated cultures compared to 3¢0 and 3¢9 £ 10 5 cfu ml ¡1 in untreated controls). In undiluted and 1:10 diluted cultures, miconazole treatment had minimal effect (2¢2 and 3¢2 £ 10 5 cfu ml ¡1 in treated cultures, and 2¢3 and 3¢3 £ 10 5 cfu ml ¡1 in untreated cultures).
Rapid transcriptional upregulation following drug exposure
We tested ve azoles (two triazoles and three imidazoles) and six additional drugs that are distinct in terms of structure and mechanism of action for their effects on ABC1 and ABC2 RNA levels (Fig. 4) . A 20-min treatment with 5 m g ml ¡1 albendazole or cycloheximide or 20 m g ml ¡1 uphenazine produced a 2-3-fold increase in ABC1 RNA. Moreover, a 5-10-fold increase was produced by treatment with 5 m g ml ¡1 miconazole or 20 m g ml ¡1 clotrimazole. Other compounds (amphotericin B, ucytosine and sulfadiazine, along with the azoles uconazole, ketoconazole and itraconazole) had little or no effect at this time point at concentrations up to 20 m g ml ¡1 (Fig. 4 and data 
Antagonism of azole activity by unrelated drugs that induce ABC1
If the ABC1 product is able to transport azoles, then upregulation of its gene following exposure to unrelated drugs such as albendazole and cycloheximide as described above should antagonize azole activity. We have recently characterized antagonism of azole activity against C. albicans by drugs which induce CDR1 or CDR2 [19] . Indeed, albendazole at concentrations of 2 or 4 m g ml ¡1 (which by itself had no effect on C. krusei)
antagonized the in vitro activity of uconazole against C. krusei up to 10 fold (Fig. 5a ). Antagonism was most readily observed at 20 and 40 m g ml ¡1 uconazole (1-2 £ MIC for this strain). Cycloheximide by itself inhibited C. krusei growth at concentrations above 0¢2 m g ml
¡1
, but at subinhibitory concentrations (0¢03 and 0¢1 m g ml ¡1 ), it antagonized the activity of 40 m g ml ¡1 uconazole by 20-40-fold (Fig. 5b) .
Expression of ABC1 and ABC2 in drug-resistant mutants
In clinical isolates of C. albicans that have lower susceptibility or resistance to azoles, increased expression of CDR1 or CDR2 genes has been observed (for reviews, see [1, 2] ). Thus, as a further test of their potential role in C. krusei MDR, we compared ABC1 and ABC2 expression in wild type cells and spontaneous mutants selected on agar medium containing 2 m g ml ¡1 miconazole or cycloheximide. (Isolation of uconazoleresistant mutants was unsuccessful due to con uent growth after prolonged incubation on plates containing 50 or 100 m g ml ¡1 uconazole.) As noted above, expression of ABC2 in log phase cells was constitutively low, and no increase relative to wild type was detected in the four drug-resistant mutants (data not shown). Similarly, no increase was detected in ABC1 RNA in the two cycloheximide-resistant mutants (Fig. 6 ). In contrast, in both miconazole-resistant mutants there was an approximately 5-fold increase in ABC1 expression.
Discussion
We have identi ed two C. krusei genes, ABC1 and ABC2, that encode close homologs of MDR-associated ABC transporters previously characterized in the yeast S. cerevisiae [10, 11] , C. albicans [12, 22] and C. glabrata [14, 15] , as well as the mould A. nidulans [13] . These genes were expressed at low constitutive levels in log phase cultures but upregulated as stationary phase was approached. ABC1 was also rapidly upregulated in cultures exposed to a diverse group of drugs; speci cally the imidazoles miconazole and clotrimazole, the microtubule inhibitor albendazole, and the protein synthesis inhibitor cycloheximide. Albendazole, which lacks activity against C. krusei, and cycloheximide at sub-inhibitory doses, antagonized the in vitro activity of uconazole.
The correlation between upregulation and antagonism suggests that uconazole, and possibly other azoles, are substrates for the ABC1-encoded transporter. This is further supported by the constitutive upregulation of ABC1 in two miconazole-resistant mutants. That ABC1 should encode an azole transporter is not unexpected, since azoles are substrates for all the ABC1 homologs noted above. Nevertheless, it should be emphasized that the current data do not directly identify the ABC1 protein as a C. krusei azole transporter, since other currently unidenti ed transporters may be co-induced with this protein and serve this role. As was done for C. albicans, C. glabrata and S. cerevisiae, gene disruption followed by susceptibility testing could be used to directly test the role of ABC1; however, this technology has not been developed for C. krusei. Similarly, heterologous expression in S. cerevisiae would permit ABC1 functional characterization, although this would not necessarily resolve its role in C. krusei. The late-log upregulation of C. krusei ABC1 and ABC2 parallels a similar observation made for C. albicans CDR1 [22] . The mechanism behind this growth-phase dependent regulation is unknown. It may be either an indirect response to changes in cell growth or metabolism, or a more direct response to the accumulation of a toxic metabolite which is a substrate for the ABC1 or ABC2 transporters. In either case, this upregulation would likely lower the azole susceptibility of late-log or stationary phase cells. Indeed, we found that stationary and late-log cells are less susceptible than mid-log cells to the lethal effects associated with brief exposure to a high concentration of miconazole. Similar results have been reported for C. albicans [20] . There are, of course, other potential explanations for this growth phase-dependent susceptibility.
C. krusei can be added to the growing list of fungi reported to rapidly upregulate the expression of speci c ABC transporter genes following exposure to a diverse set of compounds [13, 19, [22] [23] [24] . Again, the mechanism is unknown. An early study in S. cerevisiae reported that cycloheximide upregulated the expression of genes encoding transporters considered both relevant (PDR5) and irrelevant (SNQ2); i.e., with respect to their ability to transport that particular drug [23] . However, recent studies suggest this is not the case: both transporters appear capable of cycloheximide ef ux as evidenced by the increased susceptibility of a DPDR5/DSNQ2 strain compared to a DPDR5 strain [T.D. Edlind Thus, there appears to be a correlation between drugbased upregulation of an ABC transporter and its ability to transport that drug, although further studies examining this are clearly needed. Similarly, compounds which upregulate expression of the mammalian ABC transporter, P-glycoprotein, represent a subset of those that serve as its substrate [25] .
What do the results presented here reveal about the mechanism of intrinsic uconazole resistance in C. krusei? Fluconazole exposure did not lead to rapid or pronounced upregulation of ABC1 or ABC2. This is also the case in uconazole-susceptible C. albicans and S. cerevisiae, where uconazole treatment had little or no effect on CDR1 or PDR5 expression, respectively [22, 24] . Thus, it does not appear that C. krusei ABC transporter gene expression is unusually responsive to uconazole. The relative insensitivity of C. krusei lanosterol demethylase to uconazole as reported by Orozco et al. [9] may be suf cient to explain the intrinsic resistance of this organism. However, our data do indicate a potential role for C. krusei MDR upregulation in acquired azole resistance; e.g., the itraconazole resistance of a clinical isolate which was correlated with decreased accumulation [7] . It will be of interest to apply the sequences reported here to studies of ABC transporter expression in C. krusei clinical isolates with varying azole susceptibility. Also, our data further support a role for MDR upregulation in antagonism of azole activity, as recently proposed for C. albicans [19] . Since C. krusei infections are typically seen in immunocompromised patients who receive a diverse group of drugs, there is considerable potential for antagonism to occur clinically as well as in vitro. An important issue that remains to be addressed is whether or not MDR Mutant colonies were selected on plates containing 2 m g ml ¡1 miconazole (micR) or cycloheximide (cycR), isolated on drugcontaining plates, then cultured overnight in drug-free liquid medium. Cultures were diluted in drug-free medium, incubated to log phase, and RNA analyzed by slot blotting and probing with theupregulation contributes to the ability of Candida spp. to adapt to azoles, as re ected in vitro in their trailing endpoints [26] and in vivo in their non-fungicidal activity.
